Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Nov 22;83(11):1412–1417. doi: 10.1054/bjoc.2000.1477

The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer

A Nicolini 1, A Carpi 2, P Ferrari 1, L Anselmi 1, C Spinelli 2, M Conte 2, P Miccoli 2
PMCID: PMC2363419  PMID: 11076646

Abstract

The aim of this retrospective study was to assess the value of a serum tumour marker panel in selecting from among the patients with equivocal chest X-ray (CXR) or liver echography (LE) those with thoracic or liver metastases respectively. Between January 1984 and December 1999, 467 (341 non-relapsed and 126 metastatic) breast cancer patients were followed-up postoperatively. Among the 126 metastatic patients 36 showed thoracic (19 patients) or liver (17 patients) metastases, alone or in conjunction with other organs as the first evidence of distant spread. We focused on this series of 377 patients including 341 non-relapsed plus 36 with liver or thoracic metastases. The patients were followed-up after mastectomy with serial determinations of a panel of CEA-TPA-CA15.3 tumour markers, bone scintigraphy, CXR and LE. Up to December 1999, equivocal CXR occurred in 23 (6.1%) patients of whom 11 (47.8%) developed thoracic metastases; 14 (3.7%) patients showed an equivocal LE of whom 5 developed liver metastases. In the 37 patients with equivocal CXR or equivocal LE prolonged clinical and imaging follow-up over 41 ± 36 months (mean ± SD, range 3–163) was used to ascertain the presence or absence of thoracic or liver metastases. In the 23 patients with equivocal CXR the negative and positive predictive values of the tumour marker panel to predict thoracic metastases were 92% and 100% respectively. In the 14 patients with equivocal LE the negative and positive predictive values of the tumour marker panel for prediction of liver metastases were 90% and 100% respectively. This study shows that in breast cancer patients the CEA-TPA-CA15.3 tumour marker panel has a high value for selecting those patients at high risk of developing clinically evident pulmonary or liver metastases from amongst those subjects with equivocal CXR or equivocal LE. © 2000 Cancer Research Campaign http://www.bjcancer.com

Keywords: breast cancer, tumour markers, equivocal chest X-ray, equivocal liver echography

Full Text

The Full Text of this article is available as a PDF (53.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ciatto S., Herd-Smith A. The role of chest X-ray in the follow-up of primary breast cancer. Tumori. 1983 Apr 30;69(2):151–154. doi: 10.1177/030089168306900211. [DOI] [PubMed] [Google Scholar]
  2. Horton J. Follow-up of breast cancer patients. Cancer. 1984 Feb 1;53(3 Suppl):790–797. doi: 10.1002/1097-0142(19840201)53:3+<790::aid-cncr2820531330>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  3. Kruskal J. B., Kane R. A. Correlative imaging of malignant liver tumors. Semin Ultrasound CT MR. 1992 Oct;13(5):336–354. [PubMed] [Google Scholar]
  4. Loomer L., Brockschmidt J. K., Muss H. B., Saylor G. Postoperative follow-up of patients with early breast cancer. Patterns of care among clinical oncologists and a review of the literature. Cancer. 1991 Jan 1;67(1):55–60. doi: 10.1002/1097-0142(19910101)67:1<55::aid-cncr2820670111>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  5. Løgager V. B., Vestergaard A., Herrstedt J., Thomsen H. S., Zedeler K., Dombernowsky P. The limited value of routine chest X-ray in the follow-up of stage II breast cancer. Eur J Cancer. 1990;26(5):553–555. doi: 10.1016/0277-5379(90)90073-3. [DOI] [PubMed] [Google Scholar]
  6. Muss H. B., McNamara M. J., Connelly R. A. Follow-up after stage II breast cancer: a comparative study of relapsed versus nonrelapsed patients. Am J Clin Oncol. 1988 Aug;11(4):451–455. doi: 10.1097/00000421-198808000-00008. [DOI] [PubMed] [Google Scholar]
  7. Neville A. M., Patel S., Capp M., Laurence D. J., Cooper E. H., Turberville C., Coombes R. C. The monitoring role of plasma CEA alone and in association with other tumor markers in colorectal and mammary carcinoma. Cancer. 1978 Sep;42(3 Suppl):1448–1451. doi: 10.1002/1097-0142(197809)42:3+<1448::aid-cncr2820420812>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  8. Nicolini A., Anselmi L., Michelassi C., Carpi A. Prolonged survival by 'early' salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer. 1997;76(8):1106–1111. doi: 10.1038/bjc.1997.515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Nicolini A., Carpi A., Di Marco G., Giuliani L., Giordani R., Palla S. A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen, and urinary hydroxyproline in breast cancer patients. Cancer. 1989 May 15;63(10):2037–2046. doi: 10.1002/1097-0142(19890515)63:10<2037::aid-cncr2820631028>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  10. Nicolini A., Carpi A. Postoperative follow-up of breast cancer patients: overview and progress in the use of tumor markers. Tumour Biol. 2000 Jul-Aug;21(4):235–248. doi: 10.1159/000030129. [DOI] [PubMed] [Google Scholar]
  11. Nicolini A., Colombini C., Luciani L., Carpi A., Giuliani L. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer. 1991 Jul;64(1):154–158. doi: 10.1038/bjc.1991.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Nicolini A., Ferrari P., Sagripanti A., Carpi A. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Br J Cancer. 1999 Mar;79(9-10):1443–1447. doi: 10.1038/sj.bjc.6690230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pandya K. J., McFadden E. T., Kalish L. A., Tormey D. C., Taylor S. G., 4th, Falkson G. A retrospective study of earliest indicators of recurrence in patients on Eastern Cooperative Oncology Group adjuvant chemotherapy trials for breast cancer. A preliminary report. Cancer. 1985 Jan 1;55(1):202–205. doi: 10.1002/1097-0142(19850101)55:1<202::aid-cncr2820550132>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  14. Rosselli Del Turco M., Palli D., Cariddi A., Ciatto S., Pacini P., Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA. 1994 May 25;271(20):1593–1597. doi: 10.1001/jama.271.20.1593. [DOI] [PubMed] [Google Scholar]
  15. Schapira D. V., Urban N. A minimalist policy for breast cancer surveillance. JAMA. 1991 Jan 16;265(3):380–382. [PubMed] [Google Scholar]
  16. Winchester D. P., Sener S. F., Khandekar J. D., Oviedo M. A., Cunningham M. P., Caprini J. A., Burkett F. E., Scanlon E. F. Symptomatology as an indicator of recurrent or metastatic breast cancer. Cancer. 1979 Mar;43(3):956–960. doi: 10.1002/1097-0142(197903)43:3<956::aid-cncr2820430326>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES